Morgan Stanley Maintains Equal-Weight on Lakefront Biotherapeutics, Lowers Price Target to $26

Benzinga Newsdesk www.benzinga.com Neutral 77.7%

Neg 0% Neu 77.7% Pos 0%

Morgan Stanley analyst Judah Frommer maintains Lakefront Biotherapeutics (NASDAQ:LKFT) with a Equal-Weight and lowers the price target from $30 to $26.